The use of any investigational medication or device in the days prior to screening and throughout the study is prohibited. Patients who need to continue treatment with any prohibited medications Patients who have not completed the appropriate washout period for the prohibited medications For Cohort E only: prior treatment with fulvestrant is prohibited Current use of a prohibited medication Use of any prohibited medication within the timeframes Concurrent treatment with a prohibited medication. Requirement for concomitant therapy or food that is prohibited during the study Chronic use of moderate or strong CYPA modulators (inhibitor or inducer) or any other prohibited medications. A washout period of days is required prior to venetoclax dosing if a prohibited medication is discontinued. Currently taking a prohibited concomitant medication, other than a premedication, that are/is: Patients who are on any prohibited medication; a wash-out period of minimum weeks prior to registration is mandatory for the patient to be eligible for the study Current use of a prohibited medication as described A list of prohibited medications on study are listed Current use, or up to days prior use, of certain prohibited medication or requires any of these medications during treatment phase. Requiring treatment with any of the prohibited concomitant medications listed that cannot be stopped for the duration of trial participation Current use of a prohibited medication while on dabrafenib/trametinib Use of other prohibited medications within days prior to cycle day on study (Arms B and C only) (see Appendix for list of prohibited medications) Is currently taking any prohibited medication(s). Currently receiving treatment with any other agent listed on the prohibited medication list Requiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participation Use of a prohibited concomitant medication that cannot be safely discontinued or substituted. Current use of a prohibited medication or requires any of these medications during treatment with the investigational drugs. This includes excluding current medications known or suspected to be associated QT prolongation. In addition, any subject who is expected to require a QT prolonging medication while on trial should not be enrolled. Unable to discontinue the use of prohibited medications Subjects taking prohibited medications with the exception of systemic corticosteroids. A washout period of at least elimination half-lives (or as clinically indicated) should occur for prohibited medications prior to the start of treatment Receiving or anticipated to receive medications prohibited in the protocol. Patients receiving prohibited medications; prohibited medications or those to be used with caution (i.e., ketoconazole, itraconazole, ritonavir, macrolide antibiotics, erythromycin phenytoin, phenobarbital, carbamazapine, and valproic acid) Current or previous use of a prohibited medication as listed in the protocol; Current use of any of the prohibited drugs Patients receiving prohibited concomitant medications that cannot be discontinued or replaced by safe alternative medication at least half-lives of the concomitant medication or days, whichever is longer, prior to the start of pazopanib treatment. Subjects taking prohibited medications; a washout period of prohibited medications for a period of at least two weeks or as clinically indicated should occur prior to the start of treatment Current use of a prohibited medication Use of prohibited medications that cannot be changed to an alternative therapy Use of any prohibited concomitant medications within the prior weeks Any prohibited prior or concomitant therapy Use of any prohibited concomitant medications within days of registration Requiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participation Current use of a prohibited medication Current use of a prohibited medication including anticoagulants or platelet inhibitors or expected to require any of these medications during treatment with the investigational drug Treatment with prohibited medications Current use of a prohibited medication or planned use of any forbidden medications during treatment with GSK. Be taking or require the use of prohibited medications Received any treatments prohibited in this trial Co-administration of aprepitant and fosaprepitant during this study is prohibited Is currently taking any prohibited medication(s) Use of prohibited drugs Current use of a prohibited medication or requires any of these medications during treatment with study drug Prohibited treatments and or therapies Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications Any other prohibited or restricted medication as described in the study protocol. Current use of prohibited medications Any prohibited concomitant medication as per protocol within days of Screening Subject is receiving prohibited medications or treatments that cannot be discontinued/replaced by an alternative therapy Current use of a prohibited medication Treatment with prohibited medications less than or equal to days prior to\n treatment with rociletinib Current or planned use of prohibited meds Patients who are taking any of the prohibited medications; if a patient is willing to discontinue such a medication in order to participate in the study, then there must be an appropriate washout period, based on the half-life of the particular drug, prior to the start of the study treatment On a prohibited medication which cannot be stopped during the duration of HCV treatment Current use of a prohibited medication Is currently taking any prohibited medication(s) Subject is currently receiving treatment with any agent listed on the prohibited medication list Current use of a prohibited medication or requires any of these medications during treatment with the investigational drugs (details will be available in the protocol). This includes excluding current medications known or suspected to be associated QT prolongation. In addition, any subject who may require a QT prolonging medication while on trial should not be enrolled. Is currently taking any prohibited medication(s) Current use of a prohibited medication including anticoagulants or platelet inhibitors or expected to require any of these medications during treatment with the investigational drug. Prohibited Treatments and/or Restricted Therapies Patients receiving prohibited concomitant medications at the start of the study Current use of a prohibited medication or planned use of any forbidden medications during treatment with GSK. Any prohibited medication Patients receiving certain medications and/or substances that are prohibited within stated wash-out periods Current use of prohibited medication(s) or requirement for prohibited medications during study as per the study protocol. Use of anticoagulants such as warfarin is permitted; however, international normalization ratio (INR) must be monitored according to local institutional practice. Current use of any of the drugs (prohibited concomitant medications) Use of any prohibited concomitant medications within days prior to cycle , day Current use of a prohibited medication Use of other prohibited medications within half-lives or days prior to the first dose of study drugs or requires any of these medications while receiving medication on this study Current use of a prohibited medication while on dabrafenib Willing and able to discontinue prohibited concomitant medications and/or treatments for CTCL during the study Current use of a prohibited medication or requires any of these medications during treatment with lapatinib prior to study entry Any prohibited concomitant medications for therapy with afatinib or gefitinib Is on any specifically prohibited medication or requires any of these medications during treatment with pazopanib Current use of a prohibited medication or expected to require any of these medications during treatment with study treatment. Currently receiving treatment with any prohibited medication(s) Use of prohibited medications: Treatment with prohibited medications less than or equal to days prior to first day of study treatment Current use of a prohibited medication or expected to require any of these medications during treatment with the investigational drug A condition that is expected to require concomitant use of any medication listed as prohibited while on study. Use of any prohibited concomitant medications (washout period of week) Current use of a prohibited medication per protocol or expected to require any of these medications during treatment with study drug. The following medications are prohibited during the study:\r\n* Immunosuppressive agents (except to treat a drug-related adverse event) are prohibited during the study\r\n* Systemic corticosteroids > mg daily prednisone equivalent\r\n* Any concurrent chemotherapy, hormonal therapy, immunotherapy, or investigational agents for treatment of cancer are prohibited during the study Has, within weeks prior to Day , received a medication prohibited based on CYPA interaction Requires administration of a prohibited medication or treatment; Requiring treatment with any of the prohibited concomitant medications Patients who are currently receiving treatment with a prohibited medication that cannot be discontinued at least one week prior to the start of treatment: Any prohibited medication(s) or herbal preparation as described in the protocol or requires any of these medications during the study. Current use of a prohibited medication as described in the protocol. Current use of a prohibited medication Subjects who are not currently taking prohibited medication Any prohibited medication(s) as described in protocol Any prohibited medication Any prohibited medication(s), currently used or expected to be required. Current use of a prohibited medication or herbal preparation or requires any of these medications during the study. Prohibited Treatments and/or Therapies The systemic use of the following therapies are prohibited within days of first dose of study medication, or longer where indicated: Must not be on any prohibited medications. Use of any prohibited medications within days of the first dose of study medication Current use of a prohibited medication or requires any of these medications during treatment with study drug. Currently receiving treatment with any medications listed on the prohibited medication listed in the protocol Patients who are on any prohibited medication; they have to be have a wash-out period of at least weeks prior to registration, in order to be eligible for the study Patients taking prohibited medication listed in the protocol Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications At screening has received any listed prohibited prior and concomitant treatments and procedures Is receiving any prohibited drugs Patients who need to continue treatment with any prohibited medications Patients who have not completed the appropriate washout period for the prohibited medications Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not a prohibited medication Current use of a prohibited medication or requires any of these medications during treatment with GSK